The Lancet: November 16, 2007

Arne Astrup from the University of Copenhagen, Denmark, discusses a meta-analysis highlighting how the anti-obesity drug rimonabant is associated with an increased risk of depressive disorders. The meta-analysis pooled data from four randomised trials from the RIO (rimonabant in obesity) programme. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/comp...

Om Podcasten

Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.